| Literature DB >> 32034022 |
Yelena Petrosyan1, Kerry Kuluski2,3, Jan Barnsley2, Barbara Liu4, Walter P Wodchis5,3.
Abstract
OBJECTIVES: This study aimed to: (1) explore whether the quality of overall care for older people with diabetes is differentially affected by types and number of comorbid conditions and (2) examine the association between process of care measures and the likelihood of all-cause hospitalisations.Entities:
Keywords: diabetes; diabetes-concordant conditions; diabetes-discordant conditions; health & safety; multimorbidity clusters; quality in health care
Mesh:
Year: 2020 PMID: 32034022 PMCID: PMC7044838 DOI: 10.1136/bmjopen-2019-033291
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Process of care measures
| Measure | Concordant conditions | Discordant conditions | ||
| Diabetes with comorbid hypertension | Diabetes with comorbid hypertension and chronic ischaemic heart disease | Diabetes with comorbid osteoarthritis | Diabetes with comorbid osteoarthritis and major depression | |
|
| ||||
| HbA1c testing | ✓ | ✓ | ✓ | ✓ |
| Eye examination | ✓ | ✓ | ✓ | ✓ |
| Use of oral hypoglycaemic drugs | ✓ | ✓ | ✓ | ✓ |
| Use of ACE inhibitors | ✓ | ✓ | ||
| Use of angiotensin II receptor blockers | ✓ | ✓ | ||
| Use of antiplatelet drugs | ✓ | |||
| Use of statins | ✓ | |||
| Use of NSAIDs – * ‘negative’ indicator | ✓ | ✓ | ||
| Use of tetracyclic antidepressant – ’negative indicator’ | ✓ | |||
| Use of monoamine oxidase inhibitors – ‘negative indicator’ | ✓ | |||
| Use of benzodiazepines – ‘negative indicator’ | ✓ | |||
| Use of gaba receptor agonists – ’negative indicator’ | ✓ | |||
*’Negative’ indicators related to contraindicated processes because they increase the risk of adverse outcomes.
HbA1c, glycated haemoglobin; NSAIDs, non-steroidal anti-inflammatory drugs.
Baseline characteristics
| Characteristic | Diabetes with comorbid hypertension | Diabetes with comorbid hypertension and chronic ischaemic heart disease | Diabetes with comorbid osteoarthritis | Diabetes with comorbid osteoarthritis and major depression |
| Number of individuals | 273 592 | 141 947 | 255 214 | 2444 |
| Age in years, mean (SD) | 76.2 (7.18) | 77.4 (7.12) | 76.6 (7.24) | 75.7 (7.12) |
| Age in groups, n (%) (years) | ||||
| 65–74 | 127 469 (46.6) | 54 593 (38.4) | 112 046 (43.9) | 1194 (48.9) |
| 75–84 | 106 336 (38.9) | 61.883 (43.6) | 102 717 (40.2) | 906 (37.1) |
| 85–94 | 37 194 (13.6) | 23 950 (16.9) | 37 900 (14.9) | 333 (13.6) |
| 95+ | 2593 (0.9) | 1521 (1.1) | 2551 (1.0) | 11 (0.4) |
| Sex, n (%) | ||||
| Female | 154 565 (56.5) | 81 987 (57.8) | 139 951 (54.8) | 1545 (63.2) |
| Male | 119 027 (43.5) | 59 960 (42.2) | 115 263 (45.2) | 899 (36.8) |
| Number of drugs, mean (SD) | 10.6 (5.89) | 13.4 (6.52) | 12.1 (6.42) | 17.1 (7.6) |
| Number of drugs, n (%) | ||||
| ≤5 drugs | 48 210 (17.6) | 10 924 (7.7) | 33 768 (13.2) | 136 (5.7) |
| 6–10 drugs | 103 032 (37.7) | 39 583 (27.9) | 80 695 (31.6) | 433 (17.7) |
| ≥11 drugs | 122 350 (44.7) | 91 440 (64.4) | 140 751 (55.2) | 1875 (76.6) |
| Income quintiles, n (%) | ||||
| Q1 lowest income | 57 053 (21.7) | 29 478 (22.0) | 53 174 (21.6) | 589 (26.1) |
| Q2 | 58 237 (22.1) | 29 496 (22.0) | 53 884 (22.0) | 504 (22.3) |
| Q3 | 52 967 (20.1) | 26 765 (20.0) | 48 922 (20.0) | 414 (18.4) |
| Q4 | 50 668 (19.2) | 25 649 (19.1) | 47 143 (19.3) | 360 (15.0) |
| Q5 highest income | 44 653 (16.9) | 22 657 (16.9) | 41 855 (17.1) | 388 (17.2) |
| *RIO index, n (%) | ||||
| ≤40 (urban) | 214 443 (78.4) | 131 065 (92.3) | 237 312 (93.0) | 2293 (93.8) |
| >40 (rural) | 59 149 (21.6) | 10 882 (7.7) | 17,.902 (7.0) | 151 (6.2) |
| †Primary care models, n (%) | ||||
| Fee-for-service | 140 465 (68.3) | 120 557 (63.7) | 128 522 (69.2) | 1450 (67.8) |
| Capitated+ | 29 203 (14.2) | 26 685 (14.1) | 26 930 (14.5) | 297 (13.9) |
| Capitated | 35 990 (17.5) | 42 015 (22.2) | 30 273 (16.3) | 391 (18.3) |
| Comorbidities, n (%) | ||||
| 0 CC | 59 149 (21.6) | 15 859 (11.2) | 12 061 (4.7) | 77 (3.1) |
| 1 CC | 88 411 (32.3) | 33 105 (23.3) | 58 547 (22.9) | 335 (13.7) |
| 2 CC | 64 965 (23.7) | 34 350 (24.2) | 67 635 (26.5) | 495 (20.3) |
| 3 CC | 34 914 (12.8) | 26 547 (18.7) | 50 641 (19.8) | 490 (20.1) |
| 4 CC | 16 382 (6.0) | 16 972 (12.0) | 32 778 (12.8) | 428 (17.5) |
| 5 or more CC | 9771 (3.6) | 15 114 (10.7) | 33 552 (13.3) | 619 (25.3) |
| Number of primary care visits, mean (SD) | 6.1 (5.77) | 7.6 (6.99) | 7.34 (6.60) | 7.8 (7.4) |
| Duration of diabetes in years, mean (SD) | 9.90 (5.80) | 10.7 (6.02) | 10.0 (5.88) | 10.3 (6.01) |
| Duration of hypertension in years, mean (SD) | 13.1 (5.65) | 13.8 (5.44) | — | — |
| Duration of chronic ischaemic heart disease, mean (SD) | — | 7.13 (2.68) | — | — |
| Duration of osteoarthritis in years, mean (SD) | — | — | 7.17 (2.57) | 7.4 (2.61) |
| Duration of major depression, mean (SD) | — | — | — | 3.3 (1.62) |
*Geographic location (≤40=non-rural; >40=rural).
†Non-capitated models include non-rostered models and those that operate on a fee-for-service basis; capitated models include family health networks and family health organisations operating on a capitation funding scheme; and the capitated+models include family health teams and other rostered models operating on a capitated funding scheme with additional incentives for interdisciplinary care.
CC, comorbid condition; RIO, Rurality Index of Ontario.
Distribution of process and outcome measures among adults with diabetes with comorbidities
| Measure, n (%) | Diabetes with comorbid hypertension n=273 592 | Diabetes with comorbid hypertension and chronic ischaemic heart disease n=141 947 | Diabetes with comorbid osteoarthritis | Diabetes with comorbid osteoarthritis and major depression n=2444 |
| Process measures, n (%) | ||||
| Having one or two HbA1c tests per year | 124 336 (45.4) | 61 505 (43.3) | 114 746 (45.0) | 964 (39.4) |
| Having three or more HbA1c tests per year | 77 942 (28.5) | 42 194 (29.7) | 72 469 (28.4) | 669 (27.9) |
| Annual eye examination | 177 080 (64.7) | 92 623 (65.3) | 171 803 (67.3) | 1386 (56.7) |
| Use of oral hypoglycaemic drugs | 148 344 (54.2) | 72 686 (51.2) | 130 599 (51.2) | 1102 (45.1) |
| Use of ACE inhibitors | 110 641 (40.4) | 69 296 (48.8) | — | — |
| Use of ARBs | 62 169 (22.7) | 32 997 (23.3) | — | — |
| Use of antiplatelet drugs | — | 34 868 (24.6) | — | — |
| Use of statins | — | 12 845 (79.5) | — | — |
| Use of NSAIDs – ‘negative’ | — | — | 52 952 (20.8) | 452 (18.5) |
| Use of tetracyclic antidepressants – ‘negative’ | — | — | — | 348 (14.2) |
| Use of benzodiazepines – ‘negative’ | — | — | — | 860 (35.2) |
| Use of gaba receptor agonist – ‘negative’ | — | — | — | <6 (0.2) |
| Use of MAOIs – negative’ | — | — | — | 9 (0.4) |
| Continuity of care index* | ||||
| Mean, (SD) | 0.59 (0.28) | 0.51 (0.27) | 0.55 (0.26) | 0.42 (0.26) |
| Median (IQR) | 0.57 (0.36–0.82) | 0.49 (0.29–0.73) | 0.53 (0.32–0.77) | 0.36 (0.21–0.59) |
| Outcome measure, n (%) | ||||
| All-cause hospitalisations | 45 520 (15.6) | 35 157 (24.8) | 49 873 (19.5) | 536 (29.0) |
*Calculated using the Bice index.
ARBs, angiotensin II receptor blockers; HbA1c, glycated haemoglobin; MAOIs, monoamine oxidase inhibitors; NSAID, non-steroidal anti-inflammatory drugs.
Multivariable associations between process measures and the likelihood of all-cause hospitalisations among older adults with selected disease combinations
| Characteristic | Diabetes with comorbid hypertension n=273 592 | Diabetes with comorbid hypertension and chronic ischaemic heart disease n=141 947 | Diabetes with comorbid osteoarthritis n=255 214 | Diabetes with comorbid osteoarthritis and major depression n=2444 |
| All-cause hospitalisations | All-cause hospitalisations | All-cause hospitalisations | All-cause hospitalisations | |
| Having HbA1c tests | ||||
| No | Ref. | Ref. | Ref. | Ref. |
| 1 or 2 HbA1c tests | 0.90 (0.88 to 0.92) | 0.88 (0.85 to 0.91) | 0.88 (0.86 to 0.90) | 0.93 (0.76 to 1.13) |
| 3 or more HbA1c tests | 0.84 (0.82 to 0.86) | 0.86 (0.83 to 0.88) | 0.83 (0.81 to 0.85) | 0.82 (0.69 to 1.03) |
| Annual eye examination | ||||
| No | Ref. | Ref. | Ref. | Ref. |
| Yes | 0.85 (0.84 to 0.87) | 0.90 (0.88 to 0.92) | 0.89 (0.87 to 0.91) | 0.85 (0.75 to 0.97) |
| Use of oral hypoglycaemic drugs | ||||
| No | Ref. | Ref. | Ref. | Ref. |
| Yes | 0.88 (0.86 to 0.90) | 0.88 (0.86 to 0.90) | 0.92 (0.89 to 0.93) | 0.93 (0.78 to 1.10) |
| Use of ACE inhibitors | ||||
| No | Ref. | Ref. | — | — |
| Yes | 1.04 (0.99 to 1.06) | 1.03 (0.98 to 1.05) | — | — |
| Use of ARBs | ||||
| No | Ref. | Ref. | — | — |
| Yes | 0.93 (0.92 to 1.02) | 0.98 (0.96 to 1.01) | — | — |
| Use of antiplatelet drugs | ||||
| No | — | Ref. | — | — |
| Yes | — | 1.08 (1.06 to 1.11) | — | — |
| Use of statins | ||||
| No | — | Ref. | — | — |
| Yes | — | 0.89 (0.86 to 0.92) | — | — |
| Use of NSAIDs | ||||
| No | — | — | Ref. | Ref. |
| Yes | — | — | 0.99 (0.97 to 0.99) | 0.99 (0.88 to 1.12) |
| Use of tetracyclic antidepressants | ||||
| No | — | — | — | Ref. |
| Yes | — | — | — | 1.14 (0.86 to 1.32) |
| Use of benzodiazepines | ||||
| No | — | — | — | Ref. |
| Yes | — | — | — | 1.33 (1.20 to 1.48) |
| Continuity of Care (COC) index* | ||||
| COC ≤median value | Ref. | Ref. | Ref. | Ref. |
| COC >median value | 0.70 (0.69 to 0.72) | 0.74 (0.72 to 0.77) | 0.73 (0.72 to 0.74) | 0.84 (0.72 to 0.93) |
| Number of drugs | 1.06 (1.04 to 1.07) | 1.05 (1.02 to 1.07) | 1.06 (1.04 to 1.08) | 1.06 (1.05 to 1.07) |
| Age | 1.04 (1.03 to 1.05) | 1.03 (1.02 to 1.04) | 1.03 (1.02 to 1.04) | 1.02 (1.01 to 1.04) |
| Sex | ||||
| Female | Ref. | Ref. | Ref. | Ref. |
| Male | 1.40 (1.36 to 1.44) | 1.15 (1.12 to 1.18) | 1.22 (1.20 to 1.24) | 1.15 (0.97 to 1.23) |
| Income quintiles | ||||
| Q1 lowest income | Ref. | Ref. | Ref. | Ref. |
| Q2 | 0.93 (0.90 to 0.97) | 0.99 (0.97 to 1.03) | 1.02 (0.96 to 1.05) | 1.02 (0.79 to 1.3) |
| Q3 | 0.95 (0.90 to 0.99) | 1.03 (0.99 to 1.07) | 0.97 (0.94 to 0.99) | 0.99 (0.78 to 1.28) |
| Q4 | 0.89 (0.83 to 0.93) | 1.05 (0.98 to 1.09) | 0.97 (0.94 to 0.99) | 1.03 (0.79 to 1.34) |
| Q5 highest income | 0.87 (0.82 to 0.92) | 1.04 (0.95 to 1.07) | 1.48 (1.40 to 1.56) | 1.05 (0.82 to 1.35) |
| RIO index† | ||||
| ≤40 | Ref. | Ref. | Ref. | Ref. |
| >40 | 1.14 (1.09 to 1.19) | 1.16 (1.12 to 1.20) | 1.27 (0.95 to 1.57) | |
| Duration of diabetes | 1.03 (1.01 to 1.05) | 1.02 (1.01 to 1.03) | 1.19 (1.16 to 1.24) | 1.01 (0.99 to 1.02) |
| Duration of hypertension | 1.02 (1.01 to 1.03) | 1.01 (1.00 to 1.03) | 1.02 (1.01 to 1.03) | — |
| Duration of ischaemic heart disease | — | 1.01 (1.00 to 1.02) | — | — |
| Duration of osteoarthritis | — | — | 0.99 (0.97 to 1.01) | 0.92 (0.97 to 1.03) |
| Duration of depression | — | — | — | 0.95 (0.89 to 1.01) |
| Number of primary care visits | 1.02 (1.0 to 1.04) | 1.01 (1.00 to 1.03) | 1.02 (1.01 to 1.03) | 1.02 (1.01 to 1.03) |
| Primary care models‡ | ||||
| Capitated+ | Ref. | Ref. | Ref. | Ref. |
| Fee-for-service | 0.77 (0.76 to 0.79) | 0.78 (0.76 to 0.80) | 0.77 (0.76 to 0.78) | 0.83 (0.68 to 1.02) |
| Capitated | 1.09 (1.02 to 1.13) | 1.08 (0.99 to 1.13) | 1.04 (1.02 to 1.06) | 0.97 (0.51 to 1.89) |
| Comorbidities | ||||
| 0 CC | Ref. | Ref. | Ref. | Ref. |
| 1 CC | 1.17 (1.13 to 1.22) | 1.21 (1.16 to 1.27) | 1.10 (1.04 to 1.15) | 0.81 (0.62 to 1.02) |
| 2 CC | 1.37 (1.33 to 1.40) | 1.43 (1.37 to 1.48) | 1.26 (1.19 to 1.32) | 1.05 (0.68 to 1.21) |
| 3 CC | 1.65 (1.58 to 1.70) | 1.69 (1.61 to 1.75) | 1.48 (1.40 to 1.56) | 1.27 (0.71 to 1.81) |
| 4 CC | 2.00 (1.89 to 2.12) | 1.98 (1.89 to 2.09) | 1.77 (1.68 to 1.86) | 1.39 (0.82 to 1.98) |
| 5 or more CC | 2.32 (2.16 to 2.44) | 2.27 (2.15 to 2.35) | 2.12 (1.60 to 1.46) | 1.55 (0.97 to 2.23) |
*Calculated using the Bice index.
†Geographic location (≤40=non-rural; >40=rural).
‡Noncapitated models include nonrostered models and those that operate on a fee-for-service basis; capitated models include family health networks and family health organisations operating on a capitation funding scheme; and the capitated + models include family health teams and other rostered models operating on a capitated funding scheme with additional incentives for interdisciplinary care.
AOR, adjusted OR; ARBs, angiotensin II receptor blockers; HbA1c, glycated haemoglobin; NSAIDs, non-steroidal anti-inflammatory drugs.